Lexicon Pharma (LXRX) Tops Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial Results
November 1, 2016 7:00 AM EDTTHE WOODLANDS, Texas, Nov. 1, 2016 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the third quarter ended September 30, 2016 and provided an overview of key milestones for the company's lead drug candidates.
"We achieved a key milestone in the third quarter with the release of positive top-line results from our first pivotal Phase 3 clinical trial of sotagliflozin in patients with type 1 diabetes, followed by favorable results in October from a Phase 2 study that supported our Phase... More
Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
October 31, 2016 4:30 PM EDTTHE WOODLANDS, Texas, Oct. 31, 2016 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Journal of Clinical Oncology published detailed results from Lexicon's pivotal Phase 3 TELESTAR clinical study of telotristat... More
